DENALI THERAPEUTICS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 20.51 USD | +1.33% |
|
+12.02% | -4.43% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 1,673 | 10,044 | 5,447 | 3,777 | 2,966 | 2,925 | - | - |
| Enterprise Value (EV) 1 | 1,258 | 8,575 | 4,581 | 2,441 | 1,931 | 1,670 | 1,874 | 2,117 |
| P/E ratio | -8.42 x | 133 x | -18.7 x | -10.7 x | -20.2 x | -7.51 x | -7.54 x | -9.54 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 62.7 x | 29.9 x | 112 x | 34.8 x | 8.97 x | 62.3 x | 27.5 x | 11.6 x |
| EV / Revenue | 47.1 x | 25.5 x | 94.1 x | 22.5 x | 5.84 x | 35.6 x | 17.6 x | 8.42 x |
| EV / EBITDA | -6.13 x | 120 x | -16 x | -7.39 x | -10.7 x | -3.78 x | -4.37 x | -6.28 x |
| EV / FCF | -7.42 x | 20.8 x | -20.8 x | -9.3 x | -5.21 x | -3.87 x | -5.4 x | -9.58 x |
| FCF Yield | -13.5% | 4.82% | -4.8% | -10.8% | -19.2% | -25.8% | -18.5% | -10.4% |
| Price to Book | 4.22 x | 8.78 x | 5.67 x | 3.63 x | 2.86 x | 2.68 x | 3.32 x | 3.64 x |
| Nbr of stocks (in thousands) | 96,031 | 119,918 | 122,126 | 135,814 | 138,197 | 142,609 | - | - |
| Reference price 2 | 17.42 | 83.76 | 44.60 | 27.81 | 21.46 | 20.51 | 20.51 | 20.51 |
| Announcement Date | 2/27/20 | 2/25/21 | 2/28/22 | 2/27/23 | 2/27/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 26.68 | 335.7 | 48.66 | 108.5 | 330.5 | 46.94 | 106.2 | 251.4 |
| EBITDA 1 | -205.2 | 71.25 | -287.2 | -330.4 | -180 | -441.8 | -429 | -337.2 |
| EBIT 1 | -213.2 | 62.72 | -295.8 | -340.7 | -196.7 | -470.5 | -449.3 | -338.2 |
| Operating Margin | -799.1% | 18.69% | -607.78% | -314.16% | -59.51% | -1,002.31% | -422.95% | -134.51% |
| Earnings before Tax (EBT) 1 | -198 | 71.96 | -291.2 | -326 | -145.2 | -423.7 | -427.9 | -380.8 |
| Net income 1 | -197.6 | 71.14 | -290.6 | -326 | -145.2 | -424.7 | -460.3 | -395.8 |
| Net margin | -740.74% | 21.19% | -597.15% | -300.56% | -43.94% | -904.64% | -433.25% | -157.43% |
| EPS 2 | -2.070 | 0.6300 | -2.390 | -2.600 | -1.060 | -2.730 | -2.719 | -2.150 |
| Free Cash Flow 1 | -169.5 | 413.1 | -219.9 | -262.5 | -370.9 | -431.5 | -347.2 | -220.9 |
| FCF margin | -635.34% | 123.06% | -451.88% | -242.06% | -112.22% | -919.15% | -326.79% | -87.87% |
| FCF Conversion (EBITDA) | - | 579.74% | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | 580.66% | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 2/27/20 | 2/25/21 | 2/28/22 | 2/27/23 | 2/27/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 12.51 | 42.14 | 52.48 | 3.559 | 10.28 | 35.14 | 294.1 | 1.267 | - | - | 13.99 | 13.96 | 19.76 | 25 | 25 |
| EBITDA 1 | -75.03 | -64.42 | -59.34 | -105.3 | -101.3 | -110.8 | 172.8 | - | -130.4 | -130.1 | -103.1 | -114.1 | -86.64 | - | - |
| EBIT 1 | -77.12 | -66.5 | -61.42 | -107.5 | -105.3 | -120.8 | 170.5 | -113.8 | -132.6 | -132.3 | -112 | -113.9 | -110.3 | -109.9 | -103.6 |
| Operating Margin | -616.28% | -157.8% | -117.03% | -3,020.12% | -1,024.45% | -343.8% | 57.96% | -8,981.45% | - | - | -800.41% | -816.42% | -558.1% | -439.6% | -414.4% |
| Earnings before Tax (EBT) 1 | -75.84 | -65.22 | -58.77 | -103.3 | -98.68 | -109.8 | 183.4 | -99.35 | -119.4 | -101.8 | -101.8 | -105 | -104 | -109.9 | -103.6 |
| Net income 1 | -75.26 | -65.22 | -58.79 | -103.3 | -98.68 | -109.8 | 183.4 | -99.35 | -119.5 | -101.8 | -103.6 | -104.2 | -106.1 | -109.9 | -103.6 |
| Net margin | -601.41% | -154.77% | -112.03% | -2,902.47% | -959.62% | -312.4% | 62.35% | -7,841.59% | - | - | -740.31% | -746.63% | -536.79% | -439.6% | -414.4% |
| EPS 2 | -0.6200 | -0.5300 | -0.4800 | -0.8400 | -0.7500 | -0.8000 | 1.300 | -0.7200 | -0.8600 | -0.6800 | -0.6845 | -0.6875 | -0.6592 | -0.6500 | -0.6100 |
| Dividend per Share 2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 2/28/22 | 5/5/22 | 8/8/22 | 11/3/22 | 2/27/23 | 5/8/23 | 8/8/23 | 11/7/23 | 2/27/24 | 5/7/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 415 | 1,470 | 865 | 1,336 | 1,035 | 1,254 | 1,051 | 808 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -169 | 413 | -220 | -263 | -371 | -431 | -347 | -221 |
| ROE (net income / shareholders' equity) | -42% | 9.2% | -27.5% | -32.5% | -14% | -34% | -35.9% | -34.4% |
| ROA (Net income/ Total Assets) | -32.5% | 6.59% | -19.3% | -22.8% | -17.6% | -32.9% | -38.6% | -30.9% |
| Assets 1 | 607.6 | 1,079 | 1,504 | 1,432 | 823 | 1,291 | 1,191 | 1,281 |
| Book Value Per Share 2 | 4.130 | 9.550 | 7.870 | 7.670 | 7.500 | 7.650 | 6.180 | 5.640 |
| Cash Flow per Share 2 | - | - | - | -1.950 | -2.610 | 1.160 | -0.4400 | - |
| Capex 1 | 17.9 | 3.1 | 8.5 | 17.8 | 12.9 | 9.66 | 11.9 | 12.9 |
| Capex / Sales | 67.17% | 0.92% | 17.47% | 16.44% | 3.91% | 20.59% | 11.21% | 5.15% |
| Announcement Date | 2/27/20 | 2/25/21 | 2/28/22 | 2/27/23 | 2/27/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
20.51
USD
Average target price
38.67
USD
Spread / Average Target
+88.53%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -4.43% | 2.92B | |
| +9.42% | 115B | |
| +11.84% | 106B | |
| -1.05% | 21.96B | |
| -14.15% | 21.87B | |
| -5.29% | 19.21B | |
| -4.16% | 18.08B | |
| -38.29% | 17.71B | |
| +7.99% | 14.32B | |
| +36.24% | 12.42B |
- Stock Market
- Equities
- DNLI Stock
- Financials Denali Therapeutics Inc.
